fbpx
close read more
Press release

Servier appoints Angelo Paci as Oncology & Immuno-Oncology Program Leader

15/06/2022

Servier appoints Angelo Paci as Oncology & Immuno-Oncology Program Leader

Paris, France, June 15, 2022 – Servier, a global independent pharmaceutical group, today announced the appointment of Angelo Paci, PharmD, PhD., as Oncology & Immuno-Oncology Program Leader. Angelo Paci will report to Walid S. Kamoun, Director of R&D Oncology. He will also work with Fabien Schmidlin, Director of Translational Medicine, with whom he will have a functional report.

 

Angelo Paci’s responsibilities are part of Servier’s global oncology strategy to fight hard-to-treat cancers. He will contribute to the excellence of strategic pharmacokinetic and pharmacodynamic evaluations for early drug development in oncology. In particular, he will play a leading role in supporting drug reformulation efforts in pediatric oncology.

 

I am very pleased to welcome Angelo Paci whose scientific expertise in the field of oncology is internationally recognized. He will be a major contributor to the achievement of the Group’s ambitions in the field of Oncology and Immuno-Oncology”, said Walid S. Kamoun, Director of Oncology R&D at Servier.

 

 “I am delighted that Angelo Paci is joining the Servier Group. I am convinced that he will make a significant contribution to bringing new therapeutic solutions to cancer patients. His solid expertise, acquired at Gustave Roussy, the leading cancer center in Europe, will also allow us to reinforce the translational medicine approach, optimizing the medical-scientific strategy of our R&D projects”, said Fabien Schmidlin, Director of Translational Medicine et Servier.

 

Angelo Paci is Professor of Pharmacokinetics and Oncology at the Faculty of Pharmacy, Université Paris Saclay. He is a member of the French Academy of Pharmacy, the American Association for Cancer Research (AACR) and the pharmacology and oncology group of Unicancer, France. Angelo holds a Ph.D. in Pharmacy from the University of Paris V and a Ph.D. in Therapeutic Chemistry from the Faculty of Pharmacy. Angelo Paci was, just prior to joining Servier, Head of the Pharmacology Department of the Gustave Roussy Cancer Campus.

 

With 20 years of academic and hospital experience focused on oncology, Angelo has led numerous preclinical, translational and clinical projects. For more than 15 years, he has developed a clinical pharmacology activity dedicated to patients with onco-hematological malignancies including therapeutic drug monitoring and pharmacokinetic studies of anticancer drugs and metabolic biomarkers.

 

Author of more than 140 scientific publications (including articles in Cancer Discovery, Nature Comm or Journal of Clinical Oncology), Angelo Paci owns 6 patents.

 

“I am delighted to join Servier and look forward to collaborating with an international team of experts, working with and for patients, to provide innovative therapeutic solutions in the field of oncology and immuno-oncology”, said Angelo Paci.

 

About Servier

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies. More information: servier.com

 

Follow us on Social Media:Twitter Official Servier LinkedIn Official Servier Facebook Official Servier Instagram Official Servier

 

Servier press contact: Sonia Marques: presse@servier.com – Tel. +33 (0)1 55 72 40 21 / +33 (0)7 84 28 76 13

 

Press release

Last press release

Press release
06/05/2022
Servier appoints Nicolas Lévy as Chief Scientist Rare Diseases
Press release
27/04/2022
Appointment of Walid S. Kamoun, PhD. MSc., Global Head of Servier R&D Oncology
Press release
26/01/2022
Servier partners with French start-up Epigene Labs to launch a new application in the field of oncology